Literature DB >> 18204087

The difference between lupus nephritis class IV-G and IV-S in Koreans: focus on the response to cyclophosphamide induction treatment.

Y G Kim1, H W Kim, Y M Cho, J S Oh, S-S Nah, C-K Lee, B Yoo.   

Abstract

OBJECTIVES: To evaluate the response to induction therapy with intravenous (i.v.) cyclophosphamide (CYC) in Korean patients with class IV-G (diffuse global proliferative glomerulonephritis) and class IV-S (diffuse segmental proliferative glomerulonephritis) lupus nephritis (LN) according to the classification system of the International Society of Nephrology/Renal Pathology Society (ISN/RPS).
METHODS: Of the 52 patients with biopsy-proven diffuse proliferative LN, who had been treated with i.v. CYC over a 10-yr period, 42 had been treated with i.v. CYC (equal to or more than 500 mg) for 6 consecutive months and had biopsy specimens containing more than nine glomeruli. The renal pathology of these 42 patients was reclassified according to the International Society of Nephrology and the Renal Pathology Society 2003 classification, and their renal response rates and laboratory indices after induction therapy were analysed.
RESULTS: Of the 42 patients assessed, 30 (71%) had IV-G and 12 (29%) had IV-S. Pre-treatment 24 h urinary protein was significantly higher and pre-treatment concentration of anti-dsDNA antibody was significantly lower in IV-G than in IV-S patients. Following induction therapy, complete remission rates were significantly higher in patients with IV-S (67%, 8/12) than in patients with IV-G (33%, 10/30) LN.
CONCLUSIONS: Class IV-G LN responded more poorly to induction therapy with i.v. CYC pulse than class IV-S LN.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18204087     DOI: 10.1093/rheumatology/kem365

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  8 in total

1.  Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes.

Authors:  Catharina M Haring; Anke Rietveld; Jan A J G van den Brand; Jo H M Berden
Journal:  J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 10.121

2.  Characteristics and influence factors of pathologic transformation in the subclasses of class IV lupus nephritis.

Authors:  Jian-jun Gao; Guang-yan Cai; Shu-wen Liu; Li Tang; Xue-guang Zhang; Yang Yang; Pu Chen; Shu-xin Liu; Jia-yao Ji; Suo-zhu Shi; Zhong Yin; Xiang-mei Chen
Journal:  Rheumatol Int       Date:  2011-03-26       Impact factor: 2.631

3.  Outcome of reclassification of World Health Organization (WHO) class III under International Society of Nephrology-Renal Pathology Society (ISN-RPS) classification: retrospective observational study.

Authors:  Jiwon Hwang; Hyung Jin Kim; Ji-Min Oh; Joong Kyong Ahn; Yoo Sun Lee; Jaejoon Lee; Yoon-Goo Kim; Woo-Sung Huh; Jinwon Seo; Eun-Mi Koh; Hoon-Suk Cha
Journal:  Rheumatol Int       Date:  2011-03-27       Impact factor: 2.631

4.  Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis.

Authors:  Min Wook So; Bon San Koo; Yong-Gil Kim; Chang-Keun Lee; Bin Yoo
Journal:  Clin Rheumatol       Date:  2011-05-20       Impact factor: 2.980

Review 5.  Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians.

Authors:  Hitoshi Yokoyama; Hiroshi Okuyama; Hideki Yamaya
Journal:  Clin Exp Nephrol       Date:  2011-03-25       Impact factor: 2.801

6.  A Systematic Review of Interpathologist Agreement in Histologic Classification of Lupus Nephritis.

Authors:  Shobha Dasari; Ashish Chakraborty; Luan Truong; Chandra Mohan
Journal:  Kidney Int Rep       Date:  2019-06-22

Review 7.  Usefulness of ISN/RPS classification of lupus nephritis.

Authors:  Ken-Ei Sada; Hirofumi Makino
Journal:  J Korean Med Sci       Date:  2009-01-28       Impact factor: 2.153

8.  Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis.

Authors:  Prayong Vachvanichsanong; Pornsak Dissaneewate; Edward McNeil
Journal:  Int Urol Nephrol       Date:  2012-12-07       Impact factor: 2.370

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.